MorphoSys (MOR) Stock Forecast & Price Target

$18.96 0.00 (0.00%)

(As of 11/20/2024 ET)

MorphoSys - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 5 Analyst Ratings

Sell
0

Hold
4

Buy
1

Based on 5 Wall Street analysts who have issued ratings for MorphoSys in the last 12 months, the stock has a consensus rating of "Hold." Out of the 5 analysts, 4 have given a hold rating, and 1 has given a buy rating for MOR.

Consensus Price Target

$10.48
-44.75% Downside

According to the 5 analysts' twelve-month price targets for MorphoSys, the average price target is $10.48. The highest price target for MOR is $18.25, while the lowest price target for MOR is $4.75. The average price target represents a forecasted downside of -44.75% from the current price of $18.96.

Get the Latest News and Ratings for MOR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for MorphoSys and its competitors.

MOR Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	5 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$10.48	$11.78	$11.78	$11.59
Forecasted Upside	-44.75% Downside	-37.87% Downside	-37.87% Downside	154.73% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

Tesla Execs are Freaking Out (Ad)

It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

Click here to get the details.

MOR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MOR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

MorphoSys Stock vs. The Competition

Type	MorphoSys	Medical Companies	S&P 500
Consensus Rating Score	2.20	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	-44.75% Downside	26,931.54% Upside	9.83% Upside
News Sentiment Rating	Neutral News See Recent MOR News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/14/2024	Wells Fargo & Company 3 of 5 stars		Reiterated Rating	Overweight ➝ Equal Weight	$17.00 ➝ $18.25	+3.05%
1/19/2024	Morgan Stanley 3 of 5 stars		Reiterated Rating	Overweight ➝ Equal Weight
12/6/2023	Leerink Partnrs 5 of 5 stars	A. Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
12/5/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$10.00 ➝ $8.50	+17.08%
11/22/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$9.25 ➝ $4.75	+10.98%
11/21/2023	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Outperform ➝ Market Outperform	$17.00	+279.46%
7/17/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Hold
5/31/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
12/22/2022	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sell ➝ Sell	€16.00 ➝ €12.00

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:42 PM ET.

MOR Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for MorphoSys is $10.48, with a high forecast of $18.25 and a low forecast of $4.75.
: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" MOR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOR, but not buy additional shares or sell existing shares.
: According to analysts, MorphoSys's stock has a predicted downside of -44.75% based on their 12-month stock forecasts.
: Analysts like MorphoSys less than other "medical" companies. The consensus rating for MorphoSys is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MOR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)

The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.

👉[Click here to get your FREE report delivered instantly!]

This page (NASDAQ:MOR) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MorphoSys (MOR) Stock Forecast & Price Target